The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention

Abstract

Author's summary It is unclear whether ischemic risk guides the selection of antiplatelet therapy after percutaneous coronary intervention (PCI). Recently, the CHADS-P2A2RC was developed as an ischemic risk prediction model. There was a stepwise increase in the rates of major adverse cardiac and cerebral events and all-cause death according to increased CHADS-P2A2RC in the study population. No significant interactions were observed between the strata of the CHADS-P2A2RC and the antiplatelet strategies for ischemic and bleeding outcomes; the benefits of P2Y12 inhibitor monotherapy were similar even in patients with high ischemic risk. Randomized studies are needed to evaluate the utility of ischemic risk stratification to guide antiplatelet therapy selection after PCI.